FGF19 Gene Overexpression clinical trials at UCSF
1 research study open to eligible people
FGF19 gene overexpression relates to high levels of a protein that can affect cell growth. UCSF is testing TYRA-430 to check its safety and effects on advanced liver cancer and other solid tumors. These studies help understand how treatments can work on cancers linked to FGF gene changes.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: